How florbetapir could accelerate Alzheimer's research

03/7/2013 |

The practice of beta-amyloid imaging to help diagnose Alzheimer's disease, while slowly evolving, still faces challenges and uncertainties, experts say. Health care providers are hesitant to adopt the use of scans with florbetapir because the procedure is not reimbursed by Medicare and private insurers, in part because of concerns about how the tests will affect patient management. However, the reimbursement question is likely to be resolved by the end of the year, and experts are hopeful increased utilization of the imaging tests will funnel more patients into clinical trials, accelerating research into therapies.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX